Mathematical modeling of cyclic treatments of Chronic Myeloid Leukemia

Mathematical Biosciences and Engineering

Volumn 8, Issue 2, 2011, Pages 289-306

  Komarova, Natalia L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CML; Cross resistance; Drugs resistance; Mathematical modeling of cancer; The worst drug rule

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BIOLOGICAL MODEL; CHRONIC DISEASE; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; CONFERENCE PAPER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; HUMAN; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 79955002080     PISSN: 15471063     EISSN: 15510018     Source Type: Journal    
DOI: 10.3934/mbe.2011.8.289     Document Type: Conference Paper

References (50)

1. M. R. Arkin and J. A. Wells, Small-molecule inhibitors of protein-protein interactions: progressing towards the dream, Nat. Rev. Drug Discov., 3(2004), 301-317. (Pubitemid 38499758)
2. T. Asaki, Y. Sugiyama, T. Hamamoto, M. Higashioka, M. Umehara, H. Naito and T. Niwa, Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors, Bioorg. Med. Chem. Lett., 16(2006), 1421-1425. (Pubitemid 43143035)
3. D. E. Axelrod, K. A. Baggerly and M. Kimmel, Gene amplification by unequal sister chromatid exchange: probabilistic modeling and analysis of drug resistance data, J. Theor. Biol., 168(1994), 151-159. (Pubitemid 24214102)
4. N. T. J. Bailey, "The Elements of Stochastic Processes with Applications to the Natural Sciences", Wiley, New York, 1964.
5. N. Bellomo, N. K. Li and P. K. Maini, On the foundations of cancer modelling: Selected topics, speculations, and perspectives, Math. Models Methods Appl. Sci., 18(2008), 593-646. (Pubitemid 351730142)
6. Nicola Bellomo, Mark Chaplain and Elena De Angelis (eds.), "Selected Topics on Cancer Modeling: Genesis - Evolution - Immune Competition - Therapy", Boston, Birkhauser, 2008.
7. D. Bonnet and J. E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat. Med., 3(1997), 730-737. (Pubitemid 27298715)
8. H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker and M. W. Deininger, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations, Blood, 108(2006), 2332-2338. (Pubitemid 44497517)
9. H. M. Byrne, T. Alarcon, M. R. Owen, S. D. Webb and P. K. Maini, Modelling aspects of cancer dynamics: A review, Philos. Trans. R. Soc. Lond. Ser. A Math. Phys. Eng. Sci., 364(2006), 1563-1578. (Pubitemid 43893627)
10. A. J. Coldman and J. H. Goldie, Role of mathematical modeling in protocol formulation in cancer chemotherapy, Cancer Treat. Rep., 69(1985), 1041-1048.
11. A. J. Coldman and J. H. Goldie, A stochastic model for the origin and treatment of tumors contain-ing drug-resistant cells, Bull. Math. Biol., 48(1986), 279-292. (Pubitemid 17005602)
12. R. S. Day, Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy, Cancer Res., 46(1986), 3876-3885. (Pubitemid 16075878)
13. M. W. Deininger, Optimizing therapy of chronic myeloid leukemia, Experimental Hematol., 35(2007), 144-154. (Pubitemid 46427992)
14. M. W. Deininger and B. J. Druker, Specific targeted therapy of chronic myelogenous leukemia with imatinib, Pharmacol. Rev., 55(2003), 401-423. (Pubitemid 37013211)
15. T. S. Deisboeck, L. Zhang, J. Yoon and J. Costa, In silico cancer modeling: Is it ready for prime time?, Nat. Clin. Pract. Oncol., 6(2009), 34-42.
16. M. Eigen, and P. Schuster, "The Hypercycle: A Principle of Natural Self-Organization", Springer-Verlag, Berlin, New York, 1979.
17. S. Faderl, M. Talpaz, Z. Estrov and H. M. Kantarjian, Chronic myelogenous leukemia: biology and therapy, Ann. Intern. Med., 131(1999), 207-219. (Pubitemid 29365004)
18. E. A. Gaffney, The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling, J. Math. Biol., 48(2004), 375-422. (Pubitemid 40876406)
19. E. A. Gaffney, The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics, Bull. Math. Biol., 67(2005), 563-611. (Pubitemid 40466386)
20. C. W. Gardiner, "Handbook of Stochastic Methods: For Physics, Chemistry and the Natural Sciences", Springer, 2004.
21. Shea N. Gardner and Michael Fernandes, New tools for cancer chemotherapy: Computational assistance for tailoring treatments, Mol. Cancer Ther., 2(2003), 1079-1084.
22. R. A. Gatenby, J. Brown and T. Vincent, Lessons from applied ecology: Cancer control using an evolutionary double bind, Cancer Res., 69(2009), 7499-7502.
23. J. H. Goldie and A. J. Coldman, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat. Rep., 63(1979), 1727-1733. (Pubitemid 10138923)
24. J. H. Goldie and A. J. Coldman, A model for resistance of tumor cells to cancer chemotherapeutic agents, Math. Biosci., 65(1983), 291-307. (Pubitemid 14236031)
25. J. H. Goldie and A. J. Coldman, Quantitative model for multiple levels of drug resistance in clinical tumors, Cancer Treat. Rep., 67(1983), 923-931. (Pubitemid 14231384)
26. J. H. Goldie and A. J. Coldman, "Drug Resistance in Cancer: Mechanisms and Models", Cambridge University Press, 1998.
27. J. H. Goldie, A. J. Coldman and G. A. Gudauskas, Rationale for the use of alternating non-cross-resistant chemotherapy, Cancer Treat. Rep., 66(1982), 439-449. (Pubitemid 12084933)
28. L. E. Harnevo and Z. Agur, Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency, Cancer Chemother. Pharmacol., 30(1992), 469-476.
29. A. A. Katouli and N. L. Komarova, The worst drug rule revisited: Mathematical modeling of cyclic cancer treatments, Bull. Math Bio., (2010), 1-36.
30. M. Kimmel and D. N. Stivers, Time-continuous branching walk models of unstable gene amplification, Bull. Math. Biol., 56(1994), 337-357.
31. M. Kimmel, A. Swierniak and A. Polanski, Infinite-dimensional model of evolution of drug resistance of cancer cells, Jour. Math. Syst. Est. Contr., 8(1998), 1-16.
32. N. L. Komarova, Stochastic modeling of drug resistance in cancer, J. Theor. Biol., 239(2006), 351-366.
33. N. L. Komarova, A. A. Katouli and D. Wodarz, Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia, PLoS ONE, 4(2009), e4423.
34. N. L. Komarova and D. Wodarz, Drug resistance in cancer: Principles of emergence and prevention, Proc. Natl. Acad. Sci. U. S. A., 102(2005), 9714-9719. (Pubitemid 40981746)
35. L. Norton and R. Day, Potential innovations in scheduling of cancer chemotherapy, in "Important Advances in Oncology" (Vincent T. Devita, Samuel Hellman, and Steven A. Rosenberg, eds.), Lippincott, Williams & Wilkins, Philadelphia, 1985, 57-72.
36. A. S. Novozhilov, G. P. Karev and E. V. Koonin, Biological applications of the theory of birth-and-death processes, Brief. Bioinformatics, 7(2006), 70-85. (Pubitemid 44404325)
37. M. E. O'Dwyer, M. J. Mauro and B. J. Druker, Recent advancements in the treatment of chronic myelogenous leukemia, Annu. Rev. Med., 53(2002), 369-381. (Pubitemid 34177887)
38. T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, R. D. Romero, S. K. Burley and M. W. Deininger, SGX393 inhibits the CML mutant BcrAblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib, Proc. Natl. Acad. Sci. U. S. A., 105(2008), 5507-5512. (Pubitemid 351753893)
39. K. Peggs and S. Mackinnon, Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia, N. Engl. J. Med., 348(2003), 1048-1050. (Pubitemid 36302251)
40. A. Quintas-Cardama, H. Kantarjian, L. V. Abruzzo and J. Cortes, Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and negative clones during imatinib therapy, Leukemia, 21(2007), 2394-2396. (Pubitemid 350011723)
41. A. Quints-Cardama, H. Kantarjian and J. Cortes, Flying under the radar: The new wave of BCR-ABL inhibitors, Nat. Rev. Drug Discov., 6(2007), 834-848. (Pubitemid 47500507)
42. T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman, Stem cells, cancer, and cancer stem cells, Nature, 414(2001), 105-111. (Pubitemid 33041634)
43. S. Sanga, J. P. Sinek, H. B. Frieboes, M. Ferrari, J. P. Fruehauf and V. Cristini, Mathematical modeling of cancer progression and response to chemotherapy, Expert Rev. Anticancer Ther., 6(2006), 1361-1376. (Pubitemid 44697162)
44. S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, M. Amabile, E. Abruzzese, E. Orlandi, F. Radaelli, F. Ciccone, M. Tiribelli, R. di Lorenzo, C. Caracciolo, B. Izzo, F. Pane, G. Saglio, M. Baccarani and G. Martinelli, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia, Clin. Cancer Res., 12(2006), 7374-7379. (Pubitemid 46095411)
45. G. W. Swan, Role of optimal control theory in cancer chemotherapy, Math. Biosci., 101(1990), 237-284. (Pubitemid 20357967)
46. A. Swierniak, M. Kimmel and J. Smieja, Mathematical modeling as a tool for planning anticancer therapy, Eur. J. Pharmacol., 625(2009), 108-121.
47. A. Swierniak and J. Smieja, Cancer chemotherapy optimization under evolving drug resistance, Nonlin. Anal., 47(2001), 375-386. (Pubitemid 32707177)
48. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus and J. D. Griffin, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia, Nat. Rev. Cancer, 7(2007), 345-356. (Pubitemid 46652483)
49. D. Wodarz and N. L. Komarova, "Computational Biology of Cancer: Lecture Notes and Mathematical Modeling", World Scientific, 2005.
50. J. Zhang, P. L. Yang and N. S. Gray, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer, 9(2009), 28-39.